{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T23:23:48Z","timestamp":1791501828845,"version":"4.3.4"},"reference-count":195,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T00:00:00Z","timestamp":1746489600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Epstein-Barr virus (EBV) is strongly associated with multiple sclerosis (MS). It is likely to play a causal role in the pathogenesis of MS, possibly via triggering autoimmunity through molecular mimicry, autoantigenic presentation or immune dysregulation. Alternatively, evidence supports a direct role for EBV in driving MS disease activity via latent-lytic infection cycling either within the CNS or the periphery. We highlight the recent immunological and virological findings supporting the role of active EBV infection in MS, supporting an evaluation of anti-EBV strategies as potential treatments for MS.<\/jats:p>\n                  <jats:p>Anti-EBV strategies include CNS penetrant small molecule anti-viral agents targeting latent and lytic infection, and immunotherapies. Immunotherapies include EBV-specific autologous or allogeneic cytotoxic T cells (CTLs) and therapeutic EBV vaccines and\/or immune checkpoint inhibitors to rejuvenate and boost endogenous EBV-targeted CTL responses. In parallel, several licensed MS disease-modifying therapies may work via mechanisms targeting EBV directly or indirectly. B-cell depleting therapies have been shown to have anti-EBV activity; additionally, new strategies to target intrathecal B cells, plasmablasts and plasma cells are being explored, including high-dose anti-CD20 therapy, cladribine, proteasome inhibitors, BTK inhibitors, CNS-penetrant anti-CD20\/CD19 monoclonal antibodies and CD19-targeted CAR T cells. Innovative trial designs for proof-of-concept studies to test EBV antivirals and immunotherapies in MS are needed to catalyse a wave of drug development targeting EBV as a therapeutic strategy to prevent or treat MS.<\/jats:p>","DOI":"10.1093\/brain\/awaf170","type":"journal-article","created":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T08:06:49Z","timestamp":1746259609000},"page":"3057-3071","source":"Crossref","is-referenced-by-count":26,"title":["The case for targeting latent and lytic Epstein-Barr virus infection in multiple sclerosis"],"prefix":"10.1093","volume":"148","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9995-1700","authenticated-orcid":false,"given":"Gavin","family":"Giovannoni","sequence":"first","affiliation":[{"name":"Faculty of Medicine and Dentistry, Blizard Institute, Queen Mary Univesity of London , London E1 2AN ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2252-4636","authenticated-orcid":false,"given":"Louisa","family":"James","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Dentistry, Blizard Institute, Queen Mary Univesity of London , London E1 2AN ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adekunle A","family":"Adeniran","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Dentistry, Blizard Institute, Queen Mary Univesity of London , London E1 2AN ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Gold","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Dentistry, Blizard Institute, Queen Mary Univesity of London , London E1 2AN ,","place":["UK"]},{"name":"The Albion Centre, University of Sydney , Sydney, NSW 2010 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence S","family":"Young","sequence":"additional","affiliation":[{"name":"Warwick Cancer Research Centre, Warwick Medical School, University of Warwick , Coventry CV2 2DX ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L","family":"Selwood","sequence":"additional","affiliation":[{"name":"Wolfson Institute for Biomedical Research, University College London , London WC1E 6JL ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8872-8711","authenticated-orcid":false,"given":"David","family":"Baker","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Dentistry, Blizard Institute, Queen Mary Univesity of London , London E1 2AN ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2993-585X","authenticated-orcid":false,"given":"Ruth","family":"Dobson","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Dentistry, Wolfson Institute of Population Health, Queen Mary University of London , London EC1M 6BQ ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,5,6]]},"reference":[{"key":"2025090219573446300_awaf170-B1","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/S1474-4422(22)00471-9","article-title":"Epstein-Barr virus as a cause of multiple sclerosis: Opportunities for prevention and therapy","volume":"22","author":"Aloisi","year":"2023","journal-title":"Lancet Neurol"},{"key":"2025090219573446300_awaf170-B2","doi-asserted-by":"crossref","first-page":"103636","DOI":"10.1016\/j.msard.2022.103636","article-title":"Is EBV the cause of multiple sclerosis?","volume":"58","author":"Giovannoni","year":"2022","journal-title":"Mult Scler Relat Disord"},{"key":"2025090219573446300_awaf170-B3","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1177\/1352458512449682","article-title":"The risk of developing multiple sclerosis in individuals seronegative for Epstein-Barr virus: A meta-analysis","volume":"19","author":"Pakpoor","year":"2013","journal-title":"Mult Scler"},{"key":"2025090219573446300_awaf170-B4","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1126\/science.abj8222","article-title":"Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis","volume":"375","author":"Bjornevik","year":"2022","journal-title":"Science"},{"key":"2025090219573446300_awaf170-B5","doi-asserted-by":"crossref","first-page":"104434","DOI":"10.1016\/j.msard.2022.104434","article-title":"What are T-cells telling us about how EBV causes MS?","volume":"68","author":"Giovannoni","year":"2022","journal-title":"Mult Scler Relat Disord"},{"key":"2025090219573446300_awaf170-B6","doi-asserted-by":"crossref","first-page":"e1438","DOI":"10.1002\/cti2.1438","article-title":"Roadmap for understanding mechanisms on how Epstein-Barr virus triggers multiple sclerosis and for translating these discoveries in clinical trials","volume":"12","author":"Lanz","year":"2023","journal-title":"Clin Transl Immunology"},{"key":"2025090219573446300_awaf170-B7","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.3390\/cells11172757","article-title":"Altered immune response to the Epstein-Barr virus as a prerequisite for multiple sclerosis","volume":"11","author":"L\u00e4derach","year":"2022","journal-title":"Cells"},{"key":"2025090219573446300_awaf170-B8","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/08916930500484922","article-title":"Molecular mimicry in multiple sclerosis","volume":"39","author":"Sospedra","year":"2006","journal-title":"Autoimmunity"},{"key":"2025090219573446300_awaf170-B9","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.tig.2021.04.012","article-title":"Multiple sclerosis: Doubling down on MHC","volume":"37","author":"Martin","year":"2021","journal-title":"Trends Genet"},{"key":"2025090219573446300_awaf170-B10","doi-asserted-by":"crossref","first-page":"16955","DOI":"10.1073\/pnas.1902623116","article-title":"Molecular mimicry between anoctamin 2 and Epstein-Barr virus nuclear antigen 1 associates with multiple sclerosis risk","volume":"116","author":"Tengvall","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025090219573446300_awaf170-B11","doi-asserted-by":"crossref","first-page":"e184481","DOI":"10.1172\/JCI184481","article-title":"Accumulation of Epstein-Barr virus-induced cross-reactive immune responses is associated with multiple sclerosis","volume":"134","author":"Vietzen","year":"2024","journal-title":"J Clin Invest"},{"key":"2025090219573446300_awaf170-B12","doi-asserted-by":"crossref","first-page":"102332","DOI":"10.1016\/j.jaut.2019.102332","article-title":"Epstein-Barr virus nuclear antigen 1 (EBNA-1) peptides recognized by adult multiple sclerosis patient sera induce neurologic symptoms in a murine model","volume":"106","author":"Jog","year":"2020","journal-title":"J Autoimmun"},{"key":"2025090219573446300_awaf170-B13","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1212\/WNL.42.9.1798","article-title":"Antibodies against Epstein-Barr nuclear antigen (EBNA) in multiple sclerosis CSF, and two pentapeptide sequence identities between EBNA and myelin basic protein","volume":"42","author":"Bray","year":"1992","journal-title":"Neurology"},{"key":"2025090219573446300_awaf170-B14","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/0092-8674(95)90348-8","article-title":"Molecular mimicry in T cell-mediated autoimmunity: Viral peptides activate human T cell clones specific for myelin basic protein","volume":"80","author":"Wucherpfennig","year":"1995","journal-title":"Cell"},{"key":"2025090219573446300_awaf170-B15","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1038\/ni835","article-title":"A functional and structural basis for TCR cross-reactivity in multiple sclerosis","volume":"3","author":"Lang","year":"2002","journal-title":"Nat Immunol"},{"key":"2025090219573446300_awaf170-B16","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1080\/13550280490499524","article-title":"Cerebrospinal fluid CD4+ T cells from a multiple sclerosis patient cross-recognize Epstein-Barr virus and myelin basic protein","volume":"10","author":"Holm\u00f8y","year":"2004","journal-title":"J Neurovirol"},{"key":"2025090219573446300_awaf170-B17","doi-asserted-by":"crossref","first-page":"777","DOI":"10.3389\/fimmu.2017.00777","article-title":"Exposure to the Epstein-Barr viral antigen latent membrane protein 1 induces myelin-reactive antibodies In Vivo","volume":"8","author":"Lomakin","year":"2017","journal-title":"Front Immunol"},{"key":"2025090219573446300_awaf170-B18","doi-asserted-by":"crossref","first-page":"4211","DOI":"10.1096\/fj.11-190769","article-title":"Combinatorial antibody library from multiple sclerosis patients reveals antibodies that cross-react with myelin basic protein and EBV antigen","volume":"25","author":"Gabibov","year":"2011","journal-title":"FASEB J"},{"key":"2025090219573446300_awaf170-B19","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.cell.2018.08.011","article-title":"Memory B cells activate brain-homing, autoreactive CD4 T cells in multiple sclerosis","volume":"175","author":"Jelcic","year":"2018","journal-title":"Cell"},{"key":"2025090219573446300_awaf170-B20","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1016\/j.cell.2020.09.054","article-title":"HLA-DR15 Molecules jointly shape an autoreactive T cell repertoire in multiple sclerosis","volume":"183","author":"Wang","year":"2020","journal-title":"Cell"},{"key":"2025090219573446300_awaf170-B21","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/s41586-022-04432-7","article-title":"Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM","volume":"603","author":"Lanz","year":"2022","journal-title":"Nature"},{"key":"2025090219573446300_awaf170-B22","doi-asserted-by":"crossref","first-page":"5705","DOI":"10.1016\/j.cell.2023.11.015","article-title":"Ineffective control of Epstein-Barr-virus-induced autoimmunity increases the risk for multiple sclerosis","volume":"186","author":"Vietzen","year":"2023","journal-title":"Cell"},{"key":"2025090219573446300_awaf170-B23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/cei\/uxad075","article-title":"The pathogenesis of multiple sclerosis: A series of unfortunate events","volume":"214","author":"van Noort","year":"2023","journal-title":"Clin Exp Immunol"},{"key":"2025090219573446300_awaf170-B24","doi-asserted-by":"crossref","first-page":"eadg3032","DOI":"10.1126\/sciadv.adg3032","article-title":"Cross-reactive EBNA1 immunity targets alpha-crystallin B and is associated with multiple sclerosis","volume":"9","author":"Thomas","year":"2023","journal-title":"Sci Adv"},{"key":"2025090219573446300_awaf170-B25","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/jnnp.65.1.48","article-title":"Molecular approach to find target(s) for oligoclonal bands in multiple sclerosis","volume":"65","author":"Rand","year":"1998","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2025090219573446300_awaf170-B26","doi-asserted-by":"crossref","first-page":"eabn1823","DOI":"10.1126\/sciadv.abn1823","article-title":"Identification of four novel T cell autoantigens and personal autoreactive profiles in multiple sclerosis","volume":"8","author":"Bronge","year":"2022","journal-title":"Sci Adv"},{"key":"2025090219573446300_awaf170-B27","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/978-1-4614-8090-7_3","article-title":"GlialCAM, a glial cell adhesion molecule implicated in neurological disease","volume":"8","author":"Barrallo-Gimeno","year":"2014","journal-title":"Adv Neurobiol"},{"key":"2025090219573446300_awaf170-B28","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S1474-4422(12)70133-3","article-title":"Aquaporin 4 and neuromyelitis optica","volume":"11","author":"Papadopoulos","year":"2012","journal-title":"Lancet Neurol"},{"key":"2025090219573446300_awaf170-B29","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1007\/s001090100259","article-title":"Antigen-specific immunomodulation via altered peptide ligands","volume":"79","author":"Bielekova","year":"2001","journal-title":"J Mol Med"},{"key":"2025090219573446300_awaf170-B30","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/375798a0","article-title":"The small heat-shock protein alpha B-crystallin as candidate autoantigen in multiple sclerosis","volume":"375","author":"van Noort","year":"1995","journal-title":"Nature"},{"key":"2025090219573446300_awaf170-B31","doi-asserted-by":"crossref","first-page":"e0143366","DOI":"10.1371\/journal.pone.0143366","article-title":"Therapeutic intervention in multiple sclerosis with alpha B-crystallin: A randomized controlled phase IIa trial","volume":"10","author":"van Noort","year":"2015","journal-title":"PLoS One"},{"key":"2025090219573446300_awaf170-B32","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.it.2003.09.005","article-title":"Infection of autoreactive B lymphocytes with EBV, causing chronic autoimmune diseases","volume":"24","author":"Pender","year":"2003","journal-title":"Trends Immunol"},{"key":"2025090219573446300_awaf170-B33","doi-asserted-by":"crossref","first-page":"12330","DOI":"10.1128\/JVI.01699-12","article-title":"Persistence of Epstein-Barr virus in self-reactive memory B cells","volume":"86","author":"Tracy","year":"2012","journal-title":"J Virol"},{"key":"2025090219573446300_awaf170-B34","doi-asserted-by":"crossref","first-page":"e01718-16","DOI":"10.1128\/JVI.01718-16","article-title":"Epstein-Barr virus LMP1-mediated oncogenicity","volume":"91","author":"Wang","year":"2017","journal-title":"J Virol"},{"key":"2025090219573446300_awaf170-B35","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.virol.2016.10.015","article-title":"Epstein-Barr virus latent membrane protein 2A (LMP2A) enhances IL-10 production through the activation of Bruton\u2019s tyrosine kinase and STAT3","volume":"500","author":"Incrocci","year":"2017","journal-title":"Virology"},{"key":"2025090219573446300_awaf170-B36","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1006\/meth.1996.0393","article-title":"B-cell-derived IL-10: Production and function","volume":"11","author":"Burdin","year":"1997","journal-title":"Methods"},{"key":"2025090219573446300_awaf170-B37","doi-asserted-by":"crossref","first-page":"7836","DOI":"10.1073\/pnas.1231363100","article-title":"CD40 ligand is a critical effector of Epstein-Barr virus in host cell survival and transformation","volume":"100","author":"Imadome","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025090219573446300_awaf170-B38","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s12967-018-1450-6","article-title":"HLA alleles modulate EBV viral load in multiple sclerosis","volume":"16","author":"Agostini","year":"2018","journal-title":"J Transl Med"},{"key":"2025090219573446300_awaf170-B39","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1177\/09612033221100156","article-title":"Association of human leucocyte antigen class II, with viral load and immune response to Epstein-Barr virus in adult and pediatric systemic lupus erythematosus patients","volume":"31","author":"Das","year":"2022","journal-title":"Lupus"},{"key":"2025090219573446300_awaf170-B40","doi-asserted-by":"crossref","first-page":"587380","DOI":"10.3389\/fimmu.2020.587380","article-title":"Epstein-Barr virus and systemic autoimmune diseases","volume":"11","author":"Houen","year":"2020","journal-title":"Front Immunol"},{"key":"2025090219573446300_awaf170-B41","doi-asserted-by":"crossref","first-page":"623944","DOI":"10.3389\/fimmu.2020.623944","article-title":"Epstein-Barr virus and autoimmune responses in systemic lupus erythematosus","volume":"11","author":"Jog","year":"2020","journal-title":"Front Immunol"},{"key":"2025090219573446300_awaf170-B42","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ebiom.2017.01.042","article-title":"Memory B cells are major targets for effective immunotherapy in relapsing multiple sclerosis","volume":"16","author":"Baker","year":"2017","journal-title":"EBioMedicine"},{"key":"2025090219573446300_awaf170-B43","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrneurol.2016.187","article-title":"Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis","volume":"13","author":"Olsson","year":"2017","journal-title":"Nat Rev Neurol"},{"key":"2025090219573446300_awaf170-B44","first-page":"17","article-title":"Superantigens and their role in autoimmune disorders","volume":"47","author":"Schiffenbauer","year":"1999","journal-title":"Arch Immunol Ther Exp"},{"key":"2025090219573446300_awaf170-B45","doi-asserted-by":"crossref","first-page":"E6107","DOI":"10.1073\/pnas.1620415114","article-title":"Influenza infection triggers disease in a genetic model of experimental autoimmune encephalomyelitis","volume":"114","author":"Blackmore","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025090219573446300_awaf170-B46","doi-asserted-by":"crossref","first-page":"104158","DOI":"10.1016\/j.msard.2022.104158","article-title":"EBV and multiple sclerosis: Setting the research agenda","volume":"67","author":"Giovannoni","year":"2022","journal-title":"Mult Scler Relat Disord"},{"key":"2025090219573446300_awaf170-B47","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.molmed.2018.02.007","article-title":"Human endogenous retroviruses in neurological diseases","volume":"24","author":"K\u00fcry","year":"2018","journal-title":"Trends Mol Med"},{"key":"2025090219573446300_awaf170-B48","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/WCO.0b013e32815610c2","article-title":"Multiple sclerosis: The environment and causation","volume":"20","author":"Giovannoni","year":"2007","journal-title":"Curr Opin Neurol"},{"key":"2025090219573446300_awaf170-B49","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1177\/1352458517737370","article-title":"The aliens inside us: HERV-W endogenous retroviruses and multiple sclerosis","volume":"24","author":"Dolei","year":"2018","journal-title":"Mult Scler"},{"key":"2025090219573446300_awaf170-B50","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1177\/1352458510376956","article-title":"Multiple sclerosis-associated retrovirus and progressive disability of multiple sclerosis","volume":"16","author":"Sotgiu","year":"2010","journal-title":"Mult Scler"},{"issue":"Pt 1","key":"2025090219573446300_awaf170-B51","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1099\/vir.0.81890-0","article-title":"Brains and peripheral blood mononuclear cells of multiple sclerosis (MS) patients hyperexpress MS-associated retrovirus\/HERV-W endogenous retrovirus, but not human herpesvirus 6","volume":"88","author":"Mameli","year":"2007","journal-title":"J Gen Virol"},{"key":"2025090219573446300_awaf170-B52","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1177\/1352458512441381","article-title":"Human endogenous retrovirus type W envelope expression in blood and brain cells provides new insights into multiple sclerosis disease","volume":"18","author":"Perron","year":"2012","journal-title":"Mult Scler"},{"key":"2025090219573446300_awaf170-B53","doi-asserted-by":"crossref","first-page":"7636","DOI":"10.4049\/jimmunol.176.12.7636","article-title":"The envelope protein of a human endogenous retrovirus-W family activates innate immunity through CD14\/TLR4 and promotes Th1-like responses","volume":"176","author":"Rolland","year":"2006","journal-title":"J Immunol"},{"key":"2025090219573446300_awaf170-B54","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1002\/ana.23970","article-title":"Human endogenous retrovirus type W envelope protein inhibits oligodendroglial precursor cell differentiation","volume":"74","author":"Kremer","year":"2013","journal-title":"Ann Neurol"},{"key":"2025090219573446300_awaf170-B55","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1177\/1352458514554052","article-title":"A phase IIa randomised clinical study of GNbAC1, a humanised monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus in multiple sclerosis patients","volume":"21","author":"Derfuss","year":"2015","journal-title":"Mult Scler"},{"key":"2025090219573446300_awaf170-B56","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1177\/13524585211024997","article-title":"Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension study","volume":"28","author":"Hartung","year":"2022","journal-title":"Mult Scler"},{"key":"2025090219573446300_awaf170-B57","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/s41586-023-06250-x","article-title":"Locus for severity implicates CNS resilience in progression of multiple sclerosis","volume":"619","author":"International Multiple Sclerosis Genetics Consortium, MultipleMS Consortium","year":"2023","journal-title":"Nature"},{"key":"2025090219573446300_awaf170-B58","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1136\/jnnp-2014-307932","article-title":"HIV and lower risk of multiple sclerosis: Beginning to unravel a mystery using a record-linked database study","volume":"86","author":"Gold","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2025090219573446300_awaf170-B59","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/EDE.0b013e318281e48a","article-title":"Treatment of HIV and risk of multiple sclerosis","volume":"24","author":"Nex\u00f8","year":"2013","journal-title":"Epidemiology"},{"key":"2025090219573446300_awaf170-B60","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/ana.26840","article-title":"Risk of multiple sclerosis in people living with HIV: An international cohort study","volume":"95","author":"McKay","year":"2024","journal-title":"Ann Neurol"},{"key":"2025090219573446300_awaf170-B61","doi-asserted-by":"crossref","first-page":"e110","DOI":"10.1111\/j.1468-1331.2011.03430.x","article-title":"Could antiretroviral drugs be effective in multiple sclerosis? A case report","volume":"18","author":"Maruszak","year":"2011","journal-title":"Eur J Neurol"},{"key":"2025090219573446300_awaf170-B62","doi-asserted-by":"crossref","first-page":"300060521999577","DOI":"10.1177\/0300060521999577","article-title":"HIV infection and multiple sclerosis: A case with unexpected \u201cno evidence of disease activity\u201d status","volume":"49","author":"Labella","year":"2021","journal-title":"J Int Med Res"},{"key":"2025090219573446300_awaf170-B63","doi-asserted-by":"crossref","first-page":"102569","DOI":"10.1016\/j.msard.2020.102569","article-title":"Tenofovir as a treatment option for multiple sclerosis","volume":"46","author":"Torkildsen","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"2025090219573446300_awaf170-B64","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1007\/s13365-020-00876-7","article-title":"Acquisition of human immunodeficiency virus infection in a patient with multiple sclerosis: Could these conditions positively influence each other\u2019s course?","volume":"26","author":"Mainardi","year":"2020","journal-title":"J Neurovirol"},{"key":"2025090219573446300_awaf170-B65","first-page":"1041","article-title":"Multiple sclerosis and subsequent human immunodeficiency virus infection: A case with the rare comorbidity, focus on novel treatment issues and review of the literature","volume":"31","author":"Skarlis","year":"2017","journal-title":"In Vivo"},{"key":"2025090219573446300_awaf170-B66","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1007\/s13365-014-0288-9","article-title":"Multiple sclerosis remission following antiretroviral therapy in an HIV-infected man","volume":"20","author":"Chalkley","year":"2014","journal-title":"J Neurovirol"},{"key":"2025090219573446300_awaf170-B67","doi-asserted-by":"crossref","first-page":"105397","DOI":"10.1016\/j.msard.2023.105397","article-title":"Long-term MRI and clinical stability in an HIV-positive patient with multiple sclerosis on tenofovir: A case report","volume":"83","author":"Drosu","year":"2024","journal-title":"Mult Scler Relat Disord"},{"key":"2025090219573446300_awaf170-B68","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.msard.2018.02.029","article-title":"Could antiretrovirals be treating EBV in MS? A case report","volume":"22","author":"Drosu","year":"2018","journal-title":"Mult Scler Relat Disord"},{"key":"2025090219573446300_awaf170-B69","doi-asserted-by":"crossref","first-page":"12368","DOI":"10.1073\/pnas.2002392117","article-title":"Tenofovir prodrugs potently inhibit Epstein-Barr virus lytic DNA replication by targeting the viral DNA polymerase","volume":"117","author":"Drosu","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025090219573446300_awaf170-B70","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1212\/WNL.0000000000003258","article-title":"HIV-associated motor neuron disease: HERV-K activation and response to antiretroviral therapy","volume":"87","author":"Bowen","year":"2016","journal-title":"Neurology"},{"key":"2025090219573446300_awaf170-B71","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s40263-024-01153-5","article-title":"Repurposing licensed drugs with activity against Epstein-Barr virus for treatment of multiple sclerosis: A systematic approach","volume":"39","author":"Li","year":"2025","journal-title":"CNS Drugs"},{"key":"2025090219573446300_awaf170-B72","doi-asserted-by":"crossref","first-page":"840753","DOI":"10.3389\/fimmu.2022.840753","article-title":"Human herpesvirus 6A is a risk factor for multiple sclerosis","volume":"13","author":"Lundstr\u00f6m","year":"2022","journal-title":"Front Immunol"},{"key":"2025090219573446300_awaf170-B73","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1093\/brain\/awad374","article-title":"Human herpesvirus 6A and axonal injury before the clinical onset of multiple sclerosis","volume":"147","author":"Grut","year":"2024","journal-title":"Brain"},{"key":"2025090219573446300_awaf170-B74","doi-asserted-by":"crossref","first-page":"757302","DOI":"10.3389\/fimmu.2021.757302","article-title":"Cumulative roles for Epstein-Barr virus, human endogenous retroviruses, and human herpes virus-6 in driving an inflammatory cascade underlying MS pathogenesis","volume":"12","author":"Meier","year":"2021","journal-title":"Front Immunol"},{"key":"2025090219573446300_awaf170-B75","first-page":"175","article-title":"Increased tendency to spontaneous in-vitro lymphocyte transformation in clinically active multiple sclerosis","volume":"2","author":"Fraser","year":"1979","journal-title":"Lancet"},{"key":"2025090219573446300_awaf170-B76","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1177\/135245859500100204","article-title":"B-lymphoblastoid cell lines from multiple sclerosis patients and a healthy control producing a putative new human retrovirus and Epstein-Barr virus","volume":"1","author":"Munch","year":"1995","journal-title":"Mult Scler"},{"key":"2025090219573446300_awaf170-B77","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/ane.12249","article-title":"Higher incidence of Epstein-Barr virus-induced lymphocyte transformation in multiple sclerosis","volume":"130","author":"T\u00f8rring","year":"2014","journal-title":"Acta Neurol Scand"},{"key":"2025090219573446300_awaf170-B78","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.msard.2018.07.041","article-title":"Epstein-Barr virus shedding in multiple sclerosis: Similar frequencies of EBV in saliva across separate patient cohorts","volume":"25","author":"Holden","year":"2018","journal-title":"Mult Scler Relat Disord"},{"key":"2025090219573446300_awaf170-B79","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1212\/WNL.0b013e3182a841e4","article-title":"Epstein-Barr virus in oral shedding of children with multiple sclerosis","volume":"81","author":"Yea","year":"2013","journal-title":"Neurology"},{"key":"2025090219573446300_awaf170-B80","doi-asserted-by":"crossref","first-page":"e0175279","DOI":"10.1371\/journal.pone.0175279","article-title":"Epstein-Barr virus antibodies in serum and DNA load in saliva are not associated with radiological or clinical disease activity in patients with early multiple sclerosis","volume":"12","author":"Gie\u00df","year":"2017","journal-title":"PLoS One"},{"key":"2025090219573446300_awaf170-B81","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1038\/s41564-024-01699-6","article-title":"Multiple sclerosis patient-derived spontaneous B cells have distinct EBV and host gene expression profiles in active disease","volume":"9","author":"Soldan","year":"2024","journal-title":"Nat Microbiol"},{"key":"2025090219573446300_awaf170-B82","doi-asserted-by":"crossref","first-page":"e2315857121","DOI":"10.1073\/pnas.2315857121","article-title":"Expanded T lymphocytes in the cerebrospinal fluid of multiple sclerosis patients are specific for Epstein-Barr-virus-infected B cells","volume":"121","author":"Gottlieb","year":"2024","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025090219573446300_awaf170-B83","first-page":"63","article-title":"A phase 2 open-label clinical trial to determine the effect of Famciclovir on Epstein-Barr virus activity as measured by EBV shedding in the saliva of patients with multiple sclerosis","volume":"30","author":"Dobson","year":"2024"},{"key":"2025090219573446300_awaf170-B84","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.coviro.2021.11.013","article-title":"Epigenetic control of the Epstein-Barr lifecycle","volume":"52","author":"Guo","year":"2022","journal-title":"Curr Opin Virol"},{"key":"2025090219573446300_awaf170-B85","doi-asserted-by":"crossref","first-page":"200246","DOI":"10.1016\/j.tvr.2022.200246","article-title":"The oncogenic gamma herpesviruses Epstein-Barr virus (EBV) and Kaposi\u2019s sarcoma-associated herpesvirus (KSHV) hijack retinoic acid-inducible gene I (RIG-I) facilitating both viral and tumour immune evasion","volume":"14","author":"Nash","year":"2022","journal-title":"Tumour Virus Res"},{"key":"2025090219573446300_awaf170-B86","doi-asserted-by":"crossref","first-page":"955603","DOI":"10.3389\/fmicb.2022.955603","article-title":"Strategies of Epstein-Barr virus to evade innate antiviral immunity of its human host","volume":"13","author":"Albanese","year":"2022","journal-title":"Front Microbiol"},{"key":"2025090219573446300_awaf170-B87","doi-asserted-by":"crossref","first-page":"3056","DOI":"10.1158\/1078-0432.CCR-10-2578","article-title":"Epstein-Barr virus-associated B-cell lymphomas: Pathogenesis and clinical outcomes","volume":"17","author":"Saha","year":"2011","journal-title":"Clin Cancer Res"},{"key":"2025090219573446300_awaf170-B88","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1182\/blood-2005-07-2702","article-title":"Epstein-Barr virus: The impact of scientific advances on clinical practice","volume":"107","author":"Williams","year":"2006","journal-title":"Blood"},{"key":"2025090219573446300_awaf170-B89","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1159\/000479749","article-title":"Epstein-Barr virus miR-BART6-3p inhibits the RIG-I pathway","volume":"9","author":"Lu","year":"2017","journal-title":"J Innate Immun"},{"key":"2025090219573446300_awaf170-B90","doi-asserted-by":"crossref","first-page":"101652","DOI":"10.1016\/j.smim.2022.101652","article-title":"Natural killer cell responses to human oncogenic \u03b3-herpesvirus infections","volume":"60","author":"M\u00fcnz","year":"2022","journal-title":"Semin Immunol"},{"key":"2025090219573446300_awaf170-B91","doi-asserted-by":"crossref","first-page":"e1012177","DOI":"10.1371\/journal.ppat.1012177","article-title":"Heightened Epstein-Barr virus immunity and potential cross-reactivities in multiple sclerosis","volume":"20","author":"Thomas","year":"2024","journal-title":"PLoS Pathog"},{"key":"2025090219573446300_awaf170-B92","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.3389\/fimmu.2019.02193","article-title":"The T-cell response to Epstein-Barr virus-new tricks from an old dog","volume":"10","author":"Long","year":"2019","journal-title":"Front Immunol"},{"key":"2025090219573446300_awaf170-B93","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1146\/annurev-immunol-032414-112326","article-title":"The immunology of Epstein-Barr virus-induced disease","volume":"33","author":"Taylor","year":"2015","journal-title":"Annu Rev Immunol"},{"key":"2025090219573446300_awaf170-B94","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1600-065X.2010.00974.x","article-title":"Influenza vaccine immunology","volume":"239","author":"Dormitzer","year":"2011","journal-title":"Immunol Rev"},{"key":"2025090219573446300_awaf170-B95","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/ane.13401","article-title":"Neutrophil-to-lymphocyte ratio and CRP as biomarkers in multiple sclerosis: A systematic review","volume":"143","author":"Olsson","year":"2021","journal-title":"Acta Neurol Scand"},{"key":"2025090219573446300_awaf170-B96","doi-asserted-by":"crossref","first-page":"5877","DOI":"10.3390\/ijms23115877","article-title":"Current and future biomarkers in multiple sclerosis","volume":"23","author":"Yang","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"Pt 1","key":"2025090219573446300_awaf170-B97","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/brain\/120.1.1","article-title":"Daily urinary neopterin excretion as an immunological marker of disease activity in multiple sclerosis","volume":"120","author":"Giovannoni","year":"1997","journal-title":"Brain"},{"key":"2025090219573446300_awaf170-B98","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1212\/WNL.0b013e31823ed057","article-title":"Association of innate immune activation with latent Epstein-Barr virus in active MS lesions","volume":"78","author":"Tzartos","year":"2012","journal-title":"Neurology"},{"key":"2025090219573446300_awaf170-B99","doi-asserted-by":"crossref","first-page":"eabd7600","DOI":"10.1126\/sciadv.abd7600","article-title":"Gene expression signatures of target tissues in type 1 diabetes, lupus erythematosus, multiple sclerosis, and rheumatoid arthritis","volume":"7","author":"Szymczak","year":"2021","journal-title":"Sci Adv"},{"key":"2025090219573446300_awaf170-B100","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/sj.gene.6364324","article-title":"A subtype of multiple sclerosis defined by an activated immune defense program","volume":"7","author":"van Baarsen","year":"2006","journal-title":"Genes Immun"},{"key":"2025090219573446300_awaf170-B101","doi-asserted-by":"crossref","first-page":"e1927","DOI":"10.1371\/journal.pone.0001927","article-title":"Pharmacogenomics of interferon-beta therapy in multiple sclerosis: Baseline IFN signature determines pharmacological differences between patients","volume":"3","author":"van Baarsen","year":"2008","journal-title":"PLoS One"},{"issue":"Pt 12","key":"2025090219573446300_awaf170-B102","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1093\/brain\/awp228","article-title":"A type I interferon signature in monocytes is associated with poor response to interferon-beta in multiple sclerosis","volume":"132","author":"Comabella","year":"2009","journal-title":"Brain"},{"key":"2025090219573446300_awaf170-B103","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1002\/ana.22511","article-title":"Implication of the toll-like receptor 4 pathway in the response to interferon-\u03b2 in multiple sclerosis","volume":"70","author":"Bustamante","year":"2011","journal-title":"Ann Neurol"},{"key":"2025090219573446300_awaf170-B104","doi-asserted-by":"crossref","first-page":"e19262","DOI":"10.1371\/journal.pone.0019262","article-title":"Excessive biologic response to IFN\u03b2 is associated with poor treatment response in patients with multiple sclerosis","volume":"6","author":"Rudick","year":"2011","journal-title":"PLoS One"},{"key":"2025090219573446300_awaf170-B105","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1126\/science.6171035","article-title":"Intrathecal interferon reduces exacerbations of multiple sclerosis","volume":"214","author":"Jacobs","year":"1981","journal-title":"Science"},{"key":"2025090219573446300_awaf170-B106","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1001\/jama.293.20.2496","article-title":"Temporal relationship between elevation of Epstein-Barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis","volume":"293","author":"Levin","year":"2005","journal-title":"JAMA"},{"key":"2025090219573446300_awaf170-B107","doi-asserted-by":"crossref","first-page":"e000271","DOI":"10.1136\/bmjno-2022-000271","article-title":"Serum IgG levels to Epstein-Barr and measles viruses in patients with multiple sclerosis during natalizumab and interferon beta treatment","volume":"4","author":"Persson Berg","year":"2022","journal-title":"BMJ Neurol Open"},{"issue":"Pt 6","key":"2025090219573446300_awaf170-B108","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1093\/brain\/awl067","article-title":"Increased frequency and broadened specificity of latent EBV nuclear antigen-1-specific T cells in multiple sclerosis","volume":"129","author":"L\u00fcnemann","year":"2006","journal-title":"Brain"},{"key":"2025090219573446300_awaf170-B109","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jneuroim.2014.04.005","article-title":"Multiple sclerosis: The elevated antibody response to Epstein-Barr virus primarily targets, but is not confined to, the glycine-alanine repeat of Epstein-Barr nuclear antigen-1","volume":"272","author":"Ruprecht","year":"2014","journal-title":"J Neuroimmunol"},{"key":"2025090219573446300_awaf170-B110","doi-asserted-by":"crossref","first-page":"e20220650","DOI":"10.1084\/jem.20220650","article-title":"Broader Epstein-Barr virus-specific T cell receptor repertoire in patients with multiple sclerosis","volume":"219","author":"Schneider-Hohendorf","year":"2022","journal-title":"J Exp Med"},{"key":"2025090219573446300_awaf170-B111","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s40120-020-00212-5","article-title":"A systematic review and mixed treatment comparison of pharmaceutical interventions for multiple sclerosis","volume":"9","author":"Giovannoni","year":"2020","journal-title":"Neurol Ther"},{"key":"2025090219573446300_awaf170-B112","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N Engl J Med"},{"key":"2025090219573446300_awaf170-B113","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1056\/NEJMoa1917246","article-title":"Ofatumumab versus Teriflunomide in multiple sclerosis","volume":"383","author":"Hauser","year":"2020","journal-title":"N Engl J Med"},{"key":"2025090219573446300_awaf170-B114","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1056\/NEJMoa2201904","article-title":"Ublituximab versus Teriflunomide in relapsing multiple sclerosis","volume":"387","author":"Steinman","year":"2022","journal-title":"N Engl J Med"},{"key":"2025090219573446300_awaf170-B115","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1056\/NEJMoa0706383","article-title":"B-cell depletion with rituximab in relapsing-remitting multiple sclerosis","volume":"358","author":"Hauser","year":"2008","journal-title":"N Engl J Med"},{"key":"2025090219573446300_awaf170-B116","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1093\/brain\/awae244","article-title":"Broader anti-EBV TCR repertoire in multiple sclerosis: Disease specificity and treatment modulation","volume":"148","author":"Schneider-Hohendorf","year":"2025","journal-title":"Brain"},{"key":"2025090219573446300_awaf170-B117","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1001\/archneur.62.2.258","article-title":"Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis","volume":"62","author":"Monson","year":"2005","journal-title":"Arch Neurol"},{"key":"2025090219573446300_awaf170-B118","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jneuroim.2006.06.029","article-title":"Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients","volume":"180","author":"Cross","year":"2006","journal-title":"J Neuroimmunol"},{"key":"2025090219573446300_awaf170-B119","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3390\/antib10040047","article-title":"Central nervous system delivery of antibodies and their single-domain antibodies and Variable fragment derivatives with focus on intranasal nose to brain administration","volume":"10","author":"Soleimanizadeh","year":"2021","journal-title":"Antibodies (Basel)"},{"key":"2025090219573446300_awaf170-B120","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1124\/jpet.111.183483","article-title":"Exposure levels of anti-LINGO-1 Li81 antibody in the central nervous system and dose-efficacy relationships in rat spinal cord remyelination models after systemic administration","volume":"339","author":"Pepinsky","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"key":"2025090219573446300_awaf170-B121","doi-asserted-by":"crossref","first-page":"2834","DOI":"10.1093\/brain\/awy239","article-title":"Learning from other autoimmunities to understand targeting of B cells to control multiple sclerosis","volume":"141","author":"Baker","year":"2018","journal-title":"Brain"},{"key":"2025090219573446300_awaf170-B122","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/ene.14105","article-title":"Failed B cell survival factor trials support the importance of memory B cells in multiple sclerosis","volume":"27","author":"Baker","year":"2020","journal-title":"Eur J Neurol"},{"key":"2025090219573446300_awaf170-B123","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1007\/s00415-018-8830-y","article-title":"Cladribine treatment of multiple sclerosis is associated with depletion of memory B cells","volume":"265","author":"Ceronie","year":"2018","journal-title":"J Neurol"},{"key":"2025090219573446300_awaf170-B124","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/S0022-3565(25)12093-4","article-title":"The immunosuppressant leflunomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis","volume":"275","author":"Cherwinski","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"key":"2025090219573446300_awaf170-B125","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1097\/00007890-199602270-00020","article-title":"Regulation of B cell function by the immunosuppressive agent leflunomide","volume":"61","author":"Siemasko","year":"1996","journal-title":"Transplantation"},{"key":"2025090219573446300_awaf170-B126","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/1756-185X.12325","article-title":"Changes in peripheral blood B cell subsets at diagnosis and after treatment with disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: Correlation with clinical and laboratory parameters","volume":"18","author":"McComish","year":"2015","journal-title":"Int J Rheum Dis"},{"key":"2025090219573446300_awaf170-B127","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/acn3.711","article-title":"Teriflunomide induces a tolerogenic bias in blood immune cells of MS patients","volume":"6","author":"Medina","year":"2019","journal-title":"Ann Clin Transl Neurol"},{"key":"2025090219573446300_awaf170-B128","doi-asserted-by":"crossref","first-page":"e403","DOI":"10.1212\/NXI.0000000000000403","article-title":"Teriflunomide treatment reduces B cells in patients with MS","volume":"4","author":"Gandoglia","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2025090219573446300_awaf170-B129","doi-asserted-by":"crossref","first-page":"104719","DOI":"10.1016\/j.msard.2023.104719","article-title":"Teriflunomide modulates both innate and adaptive immune capacities in multiple sclerosis","volume":"75","author":"Wu","year":"2023","journal-title":"Mult Scler Relat Disord"},{"key":"2025090219573446300_awaf170-B130","doi-asserted-by":"crossref","first-page":"104377","DOI":"10.1016\/j.msard.2022.104377","article-title":"Effect of teriflunomide on Epstein-Barr virus shedding in relapsing-remitting multiple sclerosis patients: Outcomes from a real-world pilot cohort study","volume":"68","author":"Gold","year":"2022","journal-title":"Mult Scler Relat Disord"},{"key":"2025090219573446300_awaf170-B131","doi-asserted-by":"crossref","first-page":"387","DOI":"10.2217\/nmt-2021-0014","article-title":"An updated review of teriflunomide\u2019s use in multiple sclerosis","volume":"11","author":"Miller","year":"2021","journal-title":"Neurodegener Dis Manag"},{"key":"2025090219573446300_awaf170-B132","doi-asserted-by":"crossref","first-page":"1248182","DOI":"10.3389\/fimmu.2023.1248182","article-title":"Teriflunomide and Epstein-Barr virus in a Spanish multiple sclerosis cohort: Antiviral activity and clinical response","volume":"14","author":"Dom\u00ednguez-Mozo","year":"2023","journal-title":"Front Immunol"},{"key":"2025090219573446300_awaf170-B133","doi-asserted-by":"crossref","first-page":"44266","DOI":"10.18632\/oncotarget.17863","article-title":"Leflunomide\/teriflunomide inhibit Epstein-Barr virus (EBV)- induced lymphoproliferative disease and lytic viral replication","volume":"8","author":"Bilger","year":"2017","journal-title":"Oncotarget"},{"key":"2025090219573446300_awaf170-B134","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S1474-4422(14)70028-6","article-title":"Atacicept in multiple sclerosis (ATAMS): A randomised, placebo-controlled, double-blind, phase 2 trial","volume":"13","author":"Kappos","year":"2014","journal-title":"Lancet Neurol"},{"key":"2025090219573446300_awaf170-B135","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1212\/01.wnl.0000407006.93844.fb","article-title":"Interferon beta-1b is effective in relapsing-remitting multiple-sclerosis: II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial","volume":"77","author":"Paty","year":"2011","journal-title":"Neurology"},{"key":"2025090219573446300_awaf170-B136","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1358\/dot.2006.42.10.1042190","article-title":"Natalizumab","volume":"42","author":"Berger","year":"2006","journal-title":"Drugs Today"},{"key":"2025090219573446300_awaf170-B137","doi-asserted-by":"crossref","first-page":"e195","DOI":"10.1212\/NXI.0000000000000195","article-title":"Therapy with natalizumab is associated with high JCV seroconversion and rising JCV index values","volume":"3","author":"Schwab","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2025090219573446300_awaf170-B138","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1093\/infdis\/jir256","article-title":"Sequencing and analysis of JC virus DNA from natalizumab-treated PML patients","volume":"204","author":"Reid","year":"2011","journal-title":"J Infect Dis"},{"key":"2025090219573446300_awaf170-B139","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1002\/ana.24574","article-title":"Mechanisms of immune escape in central nervous system infection with neurotropic JC virus variant","volume":"79","author":"Jelcic","year":"2016","journal-title":"Ann Neurol"},{"key":"2025090219573446300_awaf170-B140","doi-asserted-by":"crossref","first-page":"e01844","DOI":"10.1128\/mBio.01844-15","article-title":"Gammaherpesvirus infection of human neuronal cells","volume":"6","author":"Jha","year":"2015","journal-title":"MBio"},{"key":"2025090219573446300_awaf170-B141","doi-asserted-by":"crossref","first-page":"29547","DOI":"10.1021\/acsomega.0c04525","article-title":"Temporal Raman spectroscopy for monitoring replication kinetics of Epstein-Barr virus infection in glial cells","volume":"5","author":"Tiwari","year":"2020","journal-title":"ACS Omega"},{"key":"2025090219573446300_awaf170-B142","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jneuroim.2017.03.013","article-title":"Massive intracerebral Epstein-Barr virus reactivation in lethal multiple sclerosis relapse after natalizumab withdrawal","volume":"307","author":"Serafini","year":"2017","journal-title":"J Neuroimmunol"},{"key":"2025090219573446300_awaf170-B143","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jneuroim.2018.03.011","article-title":"Epstein-Barr virus-associated immune reconstitution inflammatory syndrome as possible cause of fulminant multiple sclerosis relapse after natalizumab interruption","volume":"319","author":"Serafini","year":"2018","journal-title":"J Neuroimmunol"},{"key":"2025090219573446300_awaf170-B144","volume-title":"Statpearls","author":"Thapa","year":"2023"},{"key":"2025090219573446300_awaf170-B145","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.msard.2013.12.004","article-title":"Multiple sclerosis therapy and Epstein-Barr virus antibody titres","volume":"3","author":"Raffel","year":"2014","journal-title":"Mult Scler Relat Disord"},{"key":"2025090219573446300_awaf170-B146","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jns.2015.07.007","article-title":"Natalizumab modulates the humoral response against HERV-Wenv73-88 in a follow-up study of multiple sclerosis patients","volume":"357","author":"Arru","year":"2015","journal-title":"J Neurol Sci"},{"key":"2025090219573446300_awaf170-B147","doi-asserted-by":"crossref","first-page":"901312","DOI":"10.1155\/2015\/901312","article-title":"Epstein-Barr virus specific antibody response in multiple sclerosis patients during 21 months of natalizumab treatment","volume":"2015","author":"Castellazzi","year":"2015","journal-title":"Dis Markers"},{"key":"2025090219573446300_awaf170-B148","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1002\/ana.24651","article-title":"Rituximab versus fingolimod after natalizumab in multiple sclerosis patients","volume":"79","author":"Alping","year":"2016","journal-title":"Ann Neurol"},{"key":"2025090219573446300_awaf170-B149","doi-asserted-by":"crossref","first-page":"1756286419837809","DOI":"10.1177\/1756286419837809","article-title":"Post-natalizumab disease reactivation in multiple sclerosis: Systematic review and meta-analysis","volume":"12","author":"Prosperini","year":"2019","journal-title":"Ther Adv Neurol Disord"},{"key":"2025090219573446300_awaf170-B150","doi-asserted-by":"crossref","first-page":"eabi4632","DOI":"10.1126\/scitranslmed.abi4632","article-title":"Proinflammatory CD20 T cells contribute to CNS-directed autoimmunity","volume":"14","author":"Ochs","year":"2022","journal-title":"Sci Transl Med"},{"key":"2025090219573446300_awaf170-B151","doi-asserted-by":"crossref","first-page":"100630","DOI":"10.1016\/j.bj.2023.100630","article-title":"Physiological and therapeutic relevance of T cell receptor-mediated antigen trogocytosis","volume":"47","author":"Martinez-Martin","year":"2024","journal-title":"Biomed J"},{"key":"2025090219573446300_awaf170-B152","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.msard.2019.06.030","article-title":"Plasma cell and B cell-targeted treatments for use in advanced multiple sclerosis","volume":"35","author":"Baker","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"2025090219573446300_awaf170-B153","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1212\/WNL.54.5.1145","article-title":"Cladribine and progressive MS: Clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI study group","volume":"54","author":"Rice","year":"2000","journal-title":"Neurology"},{"key":"2025090219573446300_awaf170-B154","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.msard.2018.10.006","article-title":"Cladribine induces long lasting oligoclonal bands disappearance in relapsing multiple sclerosis patients: 10-year observational study","volume":"27","author":"Rejdak","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"2025090219573446300_awaf170-B155","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13075-015-0529-1","article-title":"Proteasome inhibitors as experimental therapeutics of autoimmune diseases","volume":"17","author":"Verbrugge","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"2025090219573446300_awaf170-B156","doi-asserted-by":"crossref","first-page":"672052","DOI":"10.3389\/fonc.2021.672052","article-title":"Zanubrutinib treatment of central nervous system posttransplant lymphoproliferative disorder after allogeneic hematopoietic stem cell transplantation: A case report","volume":"11","author":"Yang","year":"2021","journal-title":"Front Oncol"},{"key":"2025090219573446300_awaf170-B157","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1080\/10428194.2024.2342560","article-title":"Targets and treatments in primary CNS lymphoma","volume":"65","author":"von Roemeling","year":"2024","journal-title":"Leuk Lymphoma"},{"key":"2025090219573446300_awaf170-B158","doi-asserted-by":"crossref","first-page":"e00747-17","DOI":"10.1128\/JVI.00747-17","article-title":"Drug modulators of B cell signaling pathways and Epstein-Barr virus lytic activation","volume":"91","author":"Kosowicz","year":"2017","journal-title":"J Virol"},{"key":"2025090219573446300_awaf170-B159","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41582-023-00800-7","article-title":"Bruton tyrosine kinase inhibitors for multiple sclerosis","volume":"19","author":"Kr\u00e4mer","year":"2023","journal-title":"Nat Rev Neurol"},{"key":"2025090219573446300_awaf170-B160","doi-asserted-by":"crossref","first-page":"eaau5612","DOI":"10.1126\/scitranslmed.aau5612","article-title":"Structure-based design of small-molecule inhibitors of EBNA1 DNA binding blocks Epstein-Barr virus latent infection and tumor growth","volume":"11","author":"Messick","year":"2019","journal-title":"Sci Transl Med"},{"key":"2025090219573446300_awaf170-B161","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1182\/blood.2019004126","article-title":"Epigenetic reprogramming sensitizes immunologically silent EBV+ lymphomas to virus-directed immunotherapy","volume":"135","author":"Dalton","year":"2020","journal-title":"Blood"},{"key":"2025090219573446300_awaf170-B162","doi-asserted-by":"crossref","first-page":"361","DOI":"10.3389\/fimmu.2020.00361","article-title":"Advances in developing CAR T-cell therapy for HIV cure","volume":"11","author":"Qi","year":"2020","journal-title":"Front Immunol"},{"key":"2025090219573446300_awaf170-B163","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1097\/MOH.0000000000000083","article-title":"Epstein-Barr virus lymphoproliferative disease after hematopoietic stem cell transplant","volume":"21","author":"Rouce","year":"2014","journal-title":"Curr Opin Hematol"},{"key":"2025090219573446300_awaf170-B164","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1086\/589714","article-title":"Oropharyngeal shedding of Epstein-Barr virus in the absence of circulating B cells","volume":"198","author":"Hoover","year":"2008","journal-title":"J Infect Dis"},{"key":"2025090219573446300_awaf170-B165","doi-asserted-by":"crossref","first-page":"928","DOI":"10.3390\/v14050928","article-title":"A broad antiviral strategy: Inhibitors of human DHODH pave the way for host-targeting antivirals against emerging and re-emerging viruses","volume":"14","author":"Zheng","year":"2022","journal-title":"Viruses"},{"key":"2025090219573446300_awaf170-B166","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1053\/jinf.2001.0954","article-title":"Treatment of severe infectious mononucleosis with famciclovir","volume":"44","author":"Goldani","year":"2002","journal-title":"J Infect"},{"key":"2025090219573446300_awaf170-B167","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jcv.2010.07.008","article-title":"Antiviral treatment for severe EBV infections in apparently immunocompetent patients","volume":"49","author":"Rafailidis","year":"2010","journal-title":"J Clin Virol"},{"key":"2025090219573446300_awaf170-B168","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1097\/QAI.0b013e318247ec54","article-title":"Low cerebrospinal fluid concentrations of the nucleotide HIV reverse transcriptase inhibitor, tenofovir","volume":"59","author":"Best","year":"2012","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2025090219573446300_awaf170-B169","doi-asserted-by":"crossref","first-page":"720","DOI":"10.3390\/diagnostics12030720","article-title":"Decreased intrathecal concentrations of free light chains kappa in multiple sclerosis patients taking very high effective disease-modifying treatment","volume":"12","author":"S\u00fc\u00dfe","year":"2022","journal-title":"Diagnostics (Basel)"},{"issue":"13_Supplement","key":"2025090219573446300_awaf170-B170","doi-asserted-by":"crossref","first-page":"3631","DOI":"10.1158\/1538-7445.AM2017-3631","article-title":"Abstract 3631: Delivery of a CD20 transferrin receptor VNAR bispecific antibody to the brain for CNS lymphoma","volume":"77","author":"Walsh","year":"2017","journal-title":"Cancer Res"},{"key":"2025090219573446300_awaf170-B171","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/CJI.0000000000000092","article-title":"Efficacy of an anti-transferrin receptor 1 antibody against AIDS-related non-Hodgkin lymphoma: A brief communication","volume":"38","author":"Daniels-Wells","year":"2015","journal-title":"J Immunother"},{"key":"2025090219573446300_awaf170-B172","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3390\/v5010226","article-title":"Potential cellular functions of Epstein-Barr nuclear antigen 1 (EBNA1) of Epstein-Barr virus","volume":"5","author":"Westhoff Smith","year":"2013","journal-title":"Viruses"},{"key":"2025090219573446300_awaf170-B173","first-page":"3","article-title":"EBNA1","volume":"391","author":"Frappier","year":"2015","journal-title":"Curr Top Microbiol Immunol"},{"key":"2025090219573446300_awaf170-B174","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.ymthe.2004.12.017","article-title":"Eradication of Epstein-Barr virus episome and associated inhibition of infected tumor cell growth by adenovirus vector-mediated transduction of dominant-negative EBNA1","volume":"11","author":"Nasimuzzaman","year":"2005","journal-title":"Mol Ther"},{"key":"2025090219573446300_awaf170-B175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00432-005-0036-x","article-title":"Suppression of Epstein-Barr nuclear antigen 1 (EBNA1) by RNA interference inhibits proliferation of EBV-positive Burkitt\u2019s lymphoma cells","volume":"132","author":"Hong","year":"2006","journal-title":"J Cancer Res Clin Oncol"},{"key":"2025090219573446300_awaf170-B176","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.virol.2005.11.021","article-title":"siRNAs against the Epstein Barr virus latency replication factor, EBNA1, inhibit its function and growth of EBV-dependent tumor cells","volume":"346","author":"Yin","year":"2006","journal-title":"Virology"},{"key":"2025090219573446300_awaf170-B177","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1111\/j.1349-7006.2011.02098.x","article-title":"DNA ligand designed to antagonize EBNA1 represses Epstein-Barr virus-induced immortalization","volume":"102","author":"Yasuda","year":"2011","journal-title":"Cancer Sci"},{"key":"2025090219573446300_awaf170-B178","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1182\/blood-2010-05-285791","article-title":"Lymphomas differ in their dependence on Epstein-Barr virus","volume":"117","author":"Vereide","year":"2011","journal-title":"Blood"},{"key":"2025090219573446300_awaf170-B179","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1007\/s10120-021-01193-6","article-title":"EBNA1 inhibitors have potent and selective antitumor activity in xenograft models of Epstein-Barr virus-associated gastric cancer","volume":"24","author":"Soldan","year":"2021","journal-title":"Gastric Cancer"},{"issue":"16_suppl","key":"2025090219573446300_awaf170-B180","doi-asserted-by":"crossref","first-page":"6035","DOI":"10.1200\/JCO.2023.41.16_suppl.6035","article-title":"Phase I\/IIa clinical trial of a small molecule EBNA1 inhibitor, VK-2019, in patients with Epstein-Barr virus\u2013positive nasopharyngeal cancer with pharmacokinetic and pharmacodynamic correlative studies","volume":"41","author":"Colevas","year":"2023","journal-title":"J Clin Oncol"},{"issue":"4","key":"2025090219573446300_awaf170-B181","doi-asserted-by":"crossref","first-page":"0042","DOI":"10.1038\/s41551-017-0042","article-title":"EBNA1-targeted probe for the imaging and growth inhibition of tumours associated with the Epstein\u2013Barr virus","volume":"1","author":"Jiang","year":"2017","journal-title":"Nat. Biomed. Eng."},{"issue":"52","key":"2025090219573446300_awaf170-B182","doi-asserted-by":"crossref","first-page":"26614","DOI":"10.1073\/pnas.1915372116","article-title":"Reactivation of Epstein\u2013Barr virus by a dual-responsive fluorescent EBNA1-targeting agent with Zn 2+ -chelating function","volume":"116","author":"Jiang","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025090219573446300_awaf170-B183","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1038\/cti.2014.25","article-title":"Epstein-Barr virus and multiple sclerosis: Potential opportunities for immunotherapy","volume":"3","author":"Pender","year":"2014","journal-title":"Clin Transl Immunology"},{"key":"2025090219573446300_awaf170-B184","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1177\/1352458514536252","article-title":"Deficiency of CD8+ effector memory T cells is an early and persistent feature of multiple sclerosis","volume":"20","author":"Pender","year":"2014","journal-title":"Mult Scler"},{"key":"2025090219573446300_awaf170-B185","doi-asserted-by":"crossref","first-page":"e124714","DOI":"10.1172\/jci.insight.124714","article-title":"Epstein-Barr virus-specific T cell therapy for progressive multiple sclerosis","volume":"3","author":"Pender","year":"2018","journal-title":"JCI Insight"},{"key":"2025090219573446300_awaf170-B186","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.molmed.2019.11.003","article-title":"Epstein-Barr virus in multiple sclerosis: Theory and emerging immunotherapies","volume":"26","author":"Bar-Or","year":"2020","journal-title":"Trends Mol Med"},{"key":"2025090219573446300_awaf170-B187"},{"key":"2025090219573446300_awaf170-B188","doi-asserted-by":"crossref","first-page":"105364","DOI":"10.1016\/j.msard.2023.105364","article-title":"Emboldened or not: The potential fall-out of a failed anti-EBV trial in multiple sclerosis","volume":"81","author":"Giovannoni","year":"2024","journal-title":"Mult Scler Relat Disord"},{"key":"2025090219573446300_awaf170-B189","doi-asserted-by":"crossref","first-page":"e126","DOI":"10.1038\/cti.2016.87","article-title":"Defective T-cell control of Epstein-Barr virus infection in multiple sclerosis","volume":"6","author":"Pender","year":"2017","journal-title":"Clin Transl Immunology"},{"key":"2025090219573446300_awaf170-B190","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1084\/jem.20041679","article-title":"Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients","volume":"201","author":"Muraro","year":"2005","journal-title":"J Exp Med"},{"key":"2025090219573446300_awaf170-B191","doi-asserted-by":"crossref","first-page":"e890","DOI":"10.1212\/WNL.0000000000012449","article-title":"Autologous hematopoietic stem cell transplantation in active multiple sclerosis: A real-world case series","volume":"97","author":"Nicholas","year":"2021","journal-title":"Neurology"},{"key":"2025090219573446300_awaf170-B192","doi-asserted-by":"crossref","first-page":"104911","DOI":"10.1016\/j.msard.2023.104911","article-title":"Is it ethical to use teriflunomide as an active comparator in phase 3 trials?","volume":"78","author":"Giovannoni","year":"2023","journal-title":"Mult Scler Relat Disord"},{"key":"2025090219573446300_awaf170-B193","doi-asserted-by":"crossref","first-page":"105698","DOI":"10.1016\/j.msard.2024.105698","article-title":"Can placebo-controlled phase 2 disease-modifying therapy trials in MS still be justified?","volume":"87","author":"Giovannoni","year":"2024","journal-title":"Mult Scler Relat Disord"},{"key":"2025090219573446300_awaf170-B194","doi-asserted-by":"crossref","first-page":"106194","DOI":"10.1016\/j.msard.2024.106194","article-title":"Smouldering-associated worsening or SAW: The next therapeutic challenge in managing multiple sclerosis","volume":"92","author":"Giovannoni","year":"2024","journal-title":"Mult Scler Relat Disord"},{"key":"2025090219573446300_awaf170-B195","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/ana.22449","article-title":"Japanese macaque encephalomyelitis: A spontaneous multiple sclerosis-like disease in a nonhuman primate","volume":"70","author":"Axthelm","year":"2011","journal-title":"Ann Neurol"}],"container-title":["Brain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/brain\/advance-article-pdf\/doi\/10.1093\/brain\/awaf170\/63070123\/awaf170.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/brain\/article-pdf\/148\/9\/3057\/63070123\/awaf170.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/brain\/article-pdf\/148\/9\/3057\/63070123\/awaf170.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T23:58:12Z","timestamp":1756857492000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/brain\/article\/148\/9\/3057\/8125825"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,6]]},"references-count":195,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,5,6]]},"published-print":{"date-parts":[[2025,9,3]]}},"URL":"https:\/\/doi.org\/10.1093\/brain\/awaf170","relation":{},"ISSN":["0006-8950","1460-2156"],"issn-type":[{"value":"0006-8950","type":"print"},{"value":"1460-2156","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,5,6]]}}}